ARTICLE | Clinical News
huC242-DM1/SB-408075: Began Phase I testing
December 13, 1999 8:00 AM UTC
ImmunoGen Inc. (IMGN), Norwood, Mass. Product: huC242- DM1/SB-408075 Business: Cancer Therapeutic category: Antibody, Cytotoxic Target: CanAg Description: Humanized monoclonal antibody combined with...